Aeterna Zentaris Inc. has undergone a major transformation, rebranding itself as COSCIENS Biopharma Inc. This corporate transition reflects not only a nominal change but also a strategic overhaul aimed at better representing the company's diversified portfolio and innovative drive within the
The recent collaboration between biotech creation engines Two River and Third Rock Ventures has led to the formation of TRC 2004, which has licensed a bispecific T-cell engager (BiTE) from Genor Biopharma. TRC 2004 has acquired the ex-China rights to the CD20/CD3-targeting BiTE, known as GB261,
Freudenberg Medical, known for its contributions to biopharmaceuticals and medical devices, continues to enhance its product offerings and global footprint. Highlighted in an August 2024 article by Feliza Mirasol, the company's business expansion strategy focuses on custom single-use assemblies and
In a significant milestone for the biopharmaceutical industry, AGC Biologics' Seattle site successfully underwent a multi-product inspection by the U.S. Food and Drug Administration (FDA) in March 2024. This comprehensive evaluation was aimed at supporting Biologics License Applications (BLA) for
Arbutus Biopharma Corporation (NASDAQ: ABUS), the biopharmaceutical company known for its focus on developing treatments for chronic Hepatitis B virus (HBV) infection, recently received a noteworthy boost in its stock price target. JMP Securities raised its price objective from $4.00 to $5.00,
We haven’t stepped that deep into the 21st century, but we have already witnessed how a microscopic organism like a virus can wreak havoc. They evolve to become more resistant to our usual remedies so we have to escape them in a biological race on an atomic level. Consequently, scientists have come
The bioprocessing sector, a critical component within the Life Sciences industry, continually faces hurdles in bringing innovative technologies from development to market. BioProcess360 Partners has introduced a novel investment fund aimed at bridging this gap. By providing both capital and
Rentschler Biopharma, a fifth-generation, family-owned German biopharmaceutical company, has made tremendous strides in the field of advanced therapies. With its roots tracing back over 150 years, Rentschler has carved out a unique position in the biotechnology landscape, emphasizing innovation,
Sutro Biopharma, Inc., a clinical-stage oncology company, has garnered significant attention from the investment community. Institutional investors like Susquehanna Fundamental Investments LLC recently bolstered their holdings by acquiring 126,459 shares valued at approximately $714,000 during the
The global pharmaceutical industry is undergoing a transformative phase, driven by rapid advancements in technology, increasing demand for healthcare solutions, and strategic expansions by leading companies. Esteve Pharmaceuticals, a major player in the sector, is making headlines with its
